Title	Enzalutamide and sorafenib efficacy (part 2)
Number of Patients Enrolled	12
Number of Patients Evaluable for Toxicity	12
Number of Patients Evaluated for Efficacy	10
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 0 (0%)
Response Assessment PR	n = 1 (6%)
Response Assessment SD	n = 5 (42%)
Response Assessment PD	n = 4 (33%)
Response Assessment OTHER	n = 2 (17%)
(Median) Duration Assessments PFS	2.89 months, CI: 1.61–NR
(Median) Duration Assessments OS	6.69 months, CI: 4.60–NR
Outcome Notes	Two of 12 patients were not included in the efficacy analysis. One could not swallow enzalutamide and hence never received combination treatment, and the other had an adverse event related to sorafenib during the sorafenib run‐in and never received combination treatment. These two were not included in the efficacy end points of ORR, PFS, and OS but were assessed for safety.